Amphastar Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Amphastar Pharmaceuticals, Inc. (AMPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.30% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.30%, a 2.38% increase year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-03-31 was 3.90%, a 7.14% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 4.10%.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 4.20%, a 6.67% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.20%, a 0.00% change from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 2.44% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 4.10%, a 78.26% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.30%, a 91.67% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 4.30% 10-Q · filed 2026-08-06 | 4.00% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 3.90% 10-Q · filed 2026-05-07 | ||||
| 2025-12-31 | 4.20% 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | 4.10% 10-Q · filed 2025-11-06 | 4.20% 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | 4.20% 10-Q · filed 2026-08-06 | 4.20% 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 4.20% 10-Q · filed 2026-05-07 | ||||
| 2024-12-31 | 4.20% 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | 4.20% 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | 4.50% 10-Q · filed 2025-08-07 | 4.20% 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | 4.20% 10-Q · filed 2025-05-08 | ||||
| 2023-12-31 | 4.10% 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | 4.40% 10-Q · filed 2024-11-07 | 4.10% 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | 3.80% 10-Q · filed 2024-08-09 | 4.10% 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | 4.20% 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | 2.30% 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | 2.90% 10-Q · filed 2023-11-08 | 2.30% 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | 3.00% 10-Q · filed 2023-08-09 | 2.30% 10-Q · filed 2023-08-09 | |||
| 2022-03-31 | 2.20% 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 1.20% 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | 1.10% 10-Q · filed 2022-11-08 | 1.20% 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | 1.00% 10-Q · filed 2022-08-09 | 1.20% 10-Q · filed 2022-08-09 | |||
| 2021-03-31 | 1.30% 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | 0.80% 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | 0.50% 10-Q · filed 2021-11-09 | 0.80% 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | 0.50% 10-Q · filed 2021-08-09 | 0.80% 10-Q · filed 2021-08-09 | |||
| 2020-03-31 | 0.80% 10-Q · filed 2021-05-07 | ||||
| 2019-12-31 | 2.40% 10-K · filed 2022-03-11 | ||||
| 2019-09-30 | 1.50% 10-Q · filed 2020-11-06 | 2.40% 10-Q · filed 2020-11-06 | |||
| 2019-06-30 | 2.00% 10-Q · filed 2020-08-07 | 2.40% 10-Q · filed 2020-08-07 | |||
| 2019-03-31 | 2.50% 10-Q · filed 2020-05-11 | ||||
| 2018-12-31 | 2.70% 10-K · filed 2021-03-15 | ||||
| 2018-09-30 | 2.80% 10-Q · filed 2019-11-08 | 2.70% 10-Q · filed 2019-11-08 | |||
| 2018-06-30 | 2.80% 10-Q · filed 2019-08-09 | 2.70% 10-Q · filed 2019-08-09 | |||
| 2018-03-31 | 2.70% 10-Q · filed 2019-05-10 | ||||
| 2017-12-31 | 2.10% 10-K · filed 2020-03-16 | ||||
| 2017-09-30 | 2.00% 10-Q · filed 2018-11-09 | 2.10% 10-Q · filed 2018-11-09 | |||
| 2017-06-30 | 1.50% 10-Q · filed 2018-08-09 | 2.10% 10-Q · filed 2018-08-09 | |||
| 2017-03-31 | 2.20% 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | 1.50% 10-K · filed 2019-03-15 | ||||
| 2016-09-30 | 1.30% 10-Q · filed 2017-11-09 | 1.50% 10-Q · filed 2017-11-09 | |||
| 2016-06-30 | 0.90% 10-Q · filed 2017-08-09 | 1.50% 10-Q · filed 2017-08-09 | |||
| 2016-03-31 | 1.60% 10-Q · filed 2017-05-10 | ||||
| 2015-12-31 | 1.30% 10-K · filed 2018-03-14 | ||||
| 2015-09-30 | 2.00% 10-Q · filed 2016-11-09 | 1.30% 10-Q · filed 2016-11-09 | |||
| 2015-06-30 | 1.10% 10-Q · filed 2016-08-09 | 1.20% 10-Q · filed 2016-08-09 | |||
| 2015-03-31 | 1.30% 10-Q · filed 2016-05-10 | ||||
| 2014-12-31 | 1.70% 10-K · filed 2017-03-15 | ||||
| 2014-09-30 | 1.70% 10-Q · filed 2015-11-13 | ||||
| 2014-06-30 | 2.20% 10-Q · filed 2015-08-13 | 1.50% 10-Q · filed 2015-08-13 | 1.70% 10-Q · filed 2014-08-13 | ||
| 2014-03-31 | 1.30% 10-Q · filed 2015-05-14 | ||||
| 2013-12-31 | 1.30% 10-K · filed 2015-03-26 | ||||
| 2013-09-30 | 1.20% 10-Q · filed 2014-11-13 | 1.20% 10-Q · filed 2014-11-13 | |||
| 2013-06-30 | 1.50% 10-Q · filed 2014-08-13 | 1.50% 10-Q · filed 2014-08-13 | |||
| 2012-12-31 | 0.70% 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |